| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Inflammatory pathways (iNOS, TNF-α, IL-6); glucose metabolism (GLUT4 translocation); cancer cell proliferation (liver and bile duct cancer cells).
|
|---|---|
| ln Vitro |
In vitro, Deoxyandrographolide inhibits the LPS-induced increase in iNOS mRNA levels and the production of pro-inflammatory mediators TNF-α and IL-6. It potently inhibits the growth of liver (HepG2 and SK-Hep1) and bile duct (HuCCA-1 and RMCCA-1) cancer cells. It promotes glucose uptake through glucose transporter-4 translocation to plasma membrane in L6 myotubes.
|
| ln Vivo |
In vivo, Deoxyandrographolide exerts antihyperglycemic effect. It has anti-inflammatory, antioxidant, and hepatoprotective properties. Detailed dose-response and pharmacokinetic data in animal models are limited in publicly available literature.
|
| Enzyme Assay |
No specific cell-free enzyme/receptor binding assay protocol is detailed for Deoxyandrographolide. For diterpenoid compounds, typical cell-free assays include enzyme inhibition studies (e.g., iNOS activity assays) or receptor binding studies.
|
| Cell Assay |
Anti-inflammatory activity is assessed in LPS-stimulated macrophages. Cells are treated with Deoxyandrographolide, and endpoints include iNOS mRNA levels (qPCR), TNF-α and IL-6 production (ELISA). Anticancer activity is assessed in liver and bile duct cancer cell lines using MTT or SRB assays. Glucose uptake is measured in L6 myotubes using radioactive or fluorescent 2-DG uptake assays.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of diabetes or inflammation. Deoxyandrographolide is administered via oral gavage or intraperitoneal injection. Endpoints include blood glucose levels, inflammatory cytokine levels, and histopathology.
|
| ADME/Pharmacokinetics |
Molecular weight: 334.45 g/mol; molecular formula: C20H30O4. CAS No.: 79233-15-1. Purity: typically ≥98%. Appearance: colorless needle crystals (ether-petroleum ether) or colorless flaky crystals (acetone, ethanol, or chloroform). Optical rotation: -40° (c=1, absolute ethanol). Solubility: soluble in methanol, ethanol, acetone, pyridine, and chloroform; soluble in benzene and ether. Storage: typical for diterpenoids (desiccated, protected from light, -20°C).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural diterpenoid from Andrographis paniculata, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development.
|
| References | |
| Additional Infomation |
There have been reports that Andrographis paniculata contains deoxyandrographolide, and relevant data are available for reference.
Deoxyandrographolide is a research-grade compound, not approved for therapeutic use. It is primarily used for pharmacological research in inflammation, diabetes, and cancer. No clinical trials have been reported. Its mechanisms involve inhibition of iNOS, TNF-α, and IL-6 production, and promotion of GLUT4 translocation for glucose uptake. |
| Molecular Formula |
C20H30O4
|
|---|---|
| Molecular Weight |
334.4498
|
| Exact Mass |
334.214
|
| CAS # |
79233-15-1
|
| PubChem CID |
21679042
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
511.7±50.0 °C at 760 mmHg
|
| Flash Point |
178.2±23.6 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
2.55
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
590
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=C([C@@]2(CC[C@H]([C@@]([C@H]2CC1)(C)CO)O)C)CCC3=CCOC3=O
|
| InChi Key |
DAXSYTVXDSOSIE-HNJRGHQBSA-N
|
| InChi Code |
InChI=1S/C20H30O4/c1-13-4-7-16-19(2,10-8-17(22)20(16,3)12-21)15(13)6-5-14-9-11-24-18(14)23/h9,16-17,21-22H,4-8,10-12H2,1-3H3/t16-,17+,19-,20-/m0/s1
|
| Chemical Name |
4-[2-[(4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]ethyl]-2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~299.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9900 mL | 14.9499 mL | 29.8998 mL | |
| 5 mM | 0.5980 mL | 2.9900 mL | 5.9800 mL | |
| 10 mM | 0.2990 mL | 1.4950 mL | 2.9900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
